Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa) (EIROS)
Sponsor: BioClinica, Inc.
This observational or N/A phase trial investigates Gaucher Disease, Type 1 and MRI and is currently completed. BioClinica, Inc. leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2021 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Aug 2019 — Jan 2021 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Aug 2018 — Aug 2019 [monthly]
Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioClinica, Inc.
- CEN Biotech
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .